Clinical Trials
Company updates clinical trials of regenerative therapy for types 1 and 2 diabetes
Published in Obesity and Diabetes Week, January 16th, 2006
The main objective of these studies is to identify well-tolerated and safe doses of E1-I.N.T. in diabetes patients, and signs of efficacy by measuring parameters including insulin usage and HbA1c levels. Preliminary data from the first four type 1 diabetes patients completing the 4 week treatment period (E1-I.N.T. or placebo) showed a reduction in daytime insulin usage and a favorable safety profile when the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Diet & Nutrition
Low 25(OH)D does not affect insulin sensitivity in obesity after bariatric surgery - Fitness & Wellness
Lifestyle change improved PAI-1 levels and fibrinolysis in impaired glucose tolerance subjects - Obesity Therapy
Study found family-based behavioral treatment successfully treated obesity in children - Pharmaceutical Research
Orlistat appeared to reduce need for additional diabetes drugs regardless of weight loss - Type 2 Diabetes
A TNF-alpha G-308A polymorphism may increase nephropathy risk in obese diabetics - Adipose Tissue
Extended life in lean subjects may be due to improved insulin signaling in adipose tissue - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
